Brief: Puretech Says Deupirfenidone Slowed Lung Function Decline In IPF Patients

Puretech Health

16/12/2024 07:25

Dec 16 (Reuters) - PureTech Health PLC  PRTC.L :
    * PURETECH’S DEUPIRFENIDONE (LYT-100) SLOWED LUNG FUNCTION
DECLINE
IN PEOPLE WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AS MEASURED
BY FORCED VITAL CAPACITY (FVC), ACHIEVING THE PRIMARY AND KEY
SECONDARY ENDPOINTS IN THE ELEVATE IPF PHASE 2B TRIAL
    * PURETECH’S DEUPIRFENIDONE (LYT-100) SLOWED LUNG FUNCTION
DECLINE
IN PEOPLE WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AS MEASURED
BY FORCED VITAL CAPACITY (FVC), ACHIEVING THE PRIMARY AND KEY
SECONDARY ENDPOINTS IN THE ELEVATE IPF PHASE 2B TRIAL

Source text:  ID:nBw7v6vbsa 
Further company coverage:  PRTC.L 

 ((Reuters.Briefs@thomsonreuters.com;))